Keyword: Inovio Pharmaceutical
Here is some other vaccine news of note for this week.
Inovio and GeneOne have started a clinical study of their MERS vaccine in South Korea, where the virus took 36 lives in a 2015 outbreak.
Inovio is getting closer to producing an effective HIV vaccine. Data from an early-stage clinical study showed that its Pennvax-GP could elicit almost 100% immune response.
Health officials are in talks to deploy Merck & Co.’s experimental Ebola vaccine against a new outbreak in Congo.
European biotech Vaximm has partnered with much bigger drug companies Merck KGaA and Pfizer to test a cancer vaccine/checkpoint inhibitor combo.
Themis is the most recent company to usher a Zika vaccine to the clinic.
After successfully shepherding a Zika vaccine candidate into the clinic before any other developer, Inovio Pharmaceuticals is amping up its efforts in HIV.
The NIH's Zika vaccine will move into phase 2 testing, officials said Friday. Despite the president's threats of spending cuts, this project is fully funded.
A new Zika vaccine candidate by GeoVax showed promise in preclinical tests on mice, and the company touts it as “the best solution” to the disease.
Inovio’s Zika and MERS vaccine candidates, both the first to undergo human testing in those diseases, turned in some positive early data.